Tocilizumab Versus Baricitinib in Patients With Severe COVID-19

tocilizumab 8mg/kg single infusion (a second infusion within 48 hours can be applied upon clinician's discretion)

The baricitinib intervention consists of baricitinib at a dose of 4 mg/day (given daily for up to 14 days or until discharge from hospital, whichever occurred first); however, 2 mg/day will be given if the patient has a baseline eGFR of 30 to less than 60 mL/min/1·73 m2